WO2008074315A3 - Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm - Google Patents
Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm Download PDFInfo
- Publication number
- WO2008074315A3 WO2008074315A3 PCT/DE2007/002300 DE2007002300W WO2008074315A3 WO 2008074315 A3 WO2008074315 A3 WO 2008074315A3 DE 2007002300 W DE2007002300 W DE 2007002300W WO 2008074315 A3 WO2008074315 A3 WO 2008074315A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proadm
- marker
- diagnosis
- diseases
- risk
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT07856143T ATE552504T1 (de) | 2006-12-20 | 2007-12-20 | Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm |
CN200780047509.XA CN101611314B (zh) | 2006-12-20 | 2007-12-20 | 利用新颖标志物CT-proADM进行诊断和危险分层 |
EP07856143A EP2111552B1 (de) | 2006-12-20 | 2007-12-20 | Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm |
US12/520,159 US8436135B2 (en) | 2006-12-20 | 2007-12-20 | Diagnosis and risk stratification by determining the marker CT-proADM |
ES07856143T ES2383711T3 (es) | 2006-12-20 | 2007-12-20 | Diagnóstico y estratificación de riesgos mediante el nuevo marcador CT-proADM |
JP2009541760A JP5379018B2 (ja) | 2006-12-20 | 2007-12-20 | 新規な診断マーカーであるct−プロadmによる診断および危険性の層化 |
US13/782,027 US8853355B2 (en) | 2006-12-20 | 2013-03-01 | Diagnosis and risk stratification by determining the marker CT-proADM |
US14/478,639 US9726675B2 (en) | 2006-12-20 | 2014-09-05 | Diagnosis and risk stratification by determining the marker CT-proADM |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006060112A DE102006060112A1 (de) | 2006-12-20 | 2006-12-20 | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
DE102006060112.2 | 2006-12-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/520,159 A-371-Of-International US8436135B2 (en) | 2006-12-20 | 2007-12-20 | Diagnosis and risk stratification by determining the marker CT-proADM |
US13/782,027 Continuation US8853355B2 (en) | 2006-12-20 | 2013-03-01 | Diagnosis and risk stratification by determining the marker CT-proADM |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008074315A2 WO2008074315A2 (de) | 2008-06-26 |
WO2008074315A3 true WO2008074315A3 (de) | 2008-09-12 |
Family
ID=39431425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2007/002300 WO2008074315A2 (de) | 2006-12-20 | 2007-12-20 | Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm |
Country Status (8)
Country | Link |
---|---|
US (3) | US8436135B2 (de) |
EP (1) | EP2111552B1 (de) |
JP (1) | JP5379018B2 (de) |
CN (2) | CN101611314B (de) |
AT (1) | ATE552504T1 (de) |
DE (1) | DE102006060112A1 (de) |
ES (1) | ES2383711T3 (de) |
WO (1) | WO2008074315A2 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103119446A (zh) * | 2010-06-18 | 2013-05-22 | B.R.A.H.M.S有限公司 | 预测癌症发生的生物标志物 |
CN102428368B (zh) * | 2009-05-05 | 2015-04-22 | B.R.A.H.M.S有限公司 | 患有内皮功能/功能障碍相关疾病的患者的基于血管活性激素的分层 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1628136A1 (de) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Diagnoseverfahren für Krankheiten unter Verwendung von Copeptin |
US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
EP2353011B1 (de) * | 2008-10-07 | 2020-03-04 | B.R.A.H.M.S GmbH | Biomarker zur prognose erster unerwünschter ereignisse |
ES2431358T3 (es) * | 2008-11-11 | 2013-11-26 | B.R.A.H.M.S Gmbh | Pronóstico y evaluación del riesgo en pacientes que padecen insuficiencia cardíaca mediante la determinación de la concentración de ADM |
WO2011083145A1 (en) * | 2010-01-08 | 2011-07-14 | Cavadis B.V. | Determination of exosomel biomarkers for predicting cardiovascular events |
WO2011132086A2 (en) | 2010-04-21 | 2011-10-27 | MeMed Diagnostics, Ltd. | Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof |
EP2635904A1 (de) * | 2010-11-01 | 2013-09-11 | B.R.A.H.M.S GmbH | Prognose und risikobeurteilung von patienten mit unspezifischen beschwerden |
ES2679107T3 (es) | 2012-02-09 | 2018-08-22 | Memed Diagnostics Ltd. | Distintivos y determinantes para diagnosticar infecciones y métodos para usarlos |
EP2637023A1 (de) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Vorhersage der Ergebnisse bei Patienten mit chronisch obstruktiver Lungenerkrankung |
JP6259905B2 (ja) * | 2013-03-20 | 2018-01-10 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血圧降下治療をガイドするアドレノメジュリン |
KR20170041907A (ko) | 2014-08-14 | 2017-04-17 | 메메드 다이어그노스틱스 리미티드 | 매니폴드 및 초평면을 이용한 생물학적 데이터의 컴퓨터 분석법 |
US20170234873A1 (en) | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
CN104655849B (zh) * | 2015-02-15 | 2016-08-24 | 河北博海生物工程开发有限公司 | 一种肿瘤靶标的筛选方法 |
CN108699583B (zh) | 2016-03-03 | 2022-11-01 | 米密德诊断学有限公司 | 用于区分细菌和病毒感染的rna决定子 |
SG11201900133WA (en) | 2016-07-08 | 2019-02-27 | Sphingotec Gmbh | Adrenomedullin for assessing congestion in a subject with acute heart failure |
EP4184167A1 (de) | 2016-07-10 | 2023-05-24 | MeMed Diagnostics Ltd. | Frühdiagnose von infektionen |
CN109661578B (zh) | 2016-07-10 | 2022-05-10 | 米密德诊断学有限公司 | 用于区分细菌和病毒感染的蛋白质特征 |
EP3279667A1 (de) * | 2016-08-02 | 2018-02-07 | Abbott Laboratories | Herz-troponin i und copeptin als biomarker für kurzfristige sterblichkeit bei akuter exazerbation von chronisch obstruktiver lungenerkrankung (aecopd) |
US11353456B2 (en) | 2016-09-29 | 2022-06-07 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification for appendicitis |
EP3519833A4 (de) | 2016-09-29 | 2020-06-03 | MeMed Diagnostics Ltd. | Verfahren zur prognose und behandlung |
JP6855118B2 (ja) * | 2017-03-14 | 2021-04-07 | 東ソー株式会社 | 全身状態の良不良を評価するための情報を提供する方法及び測定試薬 |
US10209260B2 (en) | 2017-07-05 | 2019-02-19 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
EP3438668A1 (de) * | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnose und risikostratifizierung von pilzinfektionen |
ES2909399T3 (es) | 2017-09-13 | 2022-05-06 | Brahms Gmbh | Proadrenomedulina como marcador de niveles anormales de plaquetas |
BR112020005682A2 (pt) | 2017-10-18 | 2020-10-20 | Adrenomed Ag | monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm) |
EP3502706A1 (de) | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow für risikobewertung und patientenmanagement unter verwendung von procalcitonin und midregional-proadrenomedullin |
MX2020008345A (es) | 2018-02-08 | 2020-09-25 | Sphingotec Gmbh | Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia. |
WO2019229241A1 (en) * | 2018-06-01 | 2019-12-05 | B.R.A.H.M.S Gmbh | Biomarkers for the diagnosis of invasive fungal infections |
US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
WO2020201078A1 (en) | 2019-03-29 | 2020-10-08 | B.R.A.H.M.S Gmbh | Prescription of remote patient management based on biomarkers |
EP3715851A1 (de) | 2019-03-29 | 2020-09-30 | B.R.A.H.M.S GmbH | Verschreibung von fernpatientenmanagement auf der basis von biomarkern |
BR112022002856A2 (pt) | 2019-08-30 | 2022-08-09 | 4TEEN4 Pharmaceuticals GmbH | Orientação de terapia e/ou monitoramento de terapia para o tratamento de choque |
EP4023218A1 (de) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe |
EP4345109A1 (de) | 2022-09-30 | 2024-04-03 | AdrenoMed AG | Anti-adrenomedullin (adm)-bindemittel zur verwendung bei der behandlung von pädiatrischen patienten mit angeborener herzerkrankung |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007316009A (ja) * | 2006-05-29 | 2007-12-06 | Univ Of Miyazaki | アドレノメデュリン前駆体c末端ペプチドの濃度の上昇を指標として循環器疾患又は炎症性疾患を診断する方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
DE19847690A1 (de) * | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
AUPR005600A0 (en) | 2000-09-12 | 2000-10-05 | University Of Sydney, The | Diagnostic assay |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
GB0401730D0 (en) * | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
DE102005036094A1 (de) * | 2005-08-01 | 2007-02-08 | B.R.A.H.M.S Ag | In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen |
US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
US9012151B2 (en) * | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
EP2180322A1 (de) * | 2008-10-22 | 2010-04-28 | BRAHMS Aktiengesellschaft | Prognostische Biomarker zur Progression von primär chronischen Nierenerkrankungen |
JP5785086B2 (ja) * | 2008-10-31 | 2015-09-24 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン |
WO2011000020A1 (en) * | 2009-06-12 | 2011-01-06 | Sbc Research Pty Ltd | Enhanced method of detection |
WO2011023813A1 (en) * | 2009-08-28 | 2011-03-03 | Brahms Gmbh | Procalcitonin for the prognosis of adverse events |
-
2006
- 2006-12-20 DE DE102006060112A patent/DE102006060112A1/de not_active Withdrawn
-
2007
- 2007-12-20 WO PCT/DE2007/002300 patent/WO2008074315A2/de active Application Filing
- 2007-12-20 JP JP2009541760A patent/JP5379018B2/ja active Active
- 2007-12-20 AT AT07856143T patent/ATE552504T1/de active
- 2007-12-20 EP EP07856143A patent/EP2111552B1/de active Active
- 2007-12-20 CN CN200780047509.XA patent/CN101611314B/zh active Active
- 2007-12-20 ES ES07856143T patent/ES2383711T3/es active Active
- 2007-12-20 CN CN201410026248.5A patent/CN103884841B/zh active Active
- 2007-12-20 US US12/520,159 patent/US8436135B2/en active Active
-
2013
- 2013-03-01 US US13/782,027 patent/US8853355B2/en active Active
-
2014
- 2014-09-05 US US14/478,639 patent/US9726675B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007316009A (ja) * | 2006-05-29 | 2007-12-06 | Univ Of Miyazaki | アドレノメデュリン前駆体c末端ペプチドの濃度の上昇を指標として循環器疾患又は炎症性疾患を診断する方法 |
Non-Patent Citations (3)
Title |
---|
GUMUSEL BULENT ET AL: "Adrenotensin: An adrenomedullin gene product contracts pulmonary blood vessels", PEPTIDES (TARRYTOWN), vol. 17, no. 3, 1996, pages 461 - 465, XP002484481, ISSN: 0196-9781 * |
STRUCK J ET AL: "Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients", PEPTIDES, ELSEVIER, AMSTERDAM, vol. 25, no. 8, 1 August 2004 (2004-08-01), pages 1369 - 1372, XP004551479, ISSN: 0196-9781 * |
ZHOU LAN ET AL: "Vasoactive effects of adrenotensin and its interactions with adrenomedullin", CHINESE MEDICAL JOURNAL (ENGLISH EDITION), vol. 113, no. 3, March 2000 (2000-03-01), pages 269 - 271, XP002484524, ISSN: 0366-6999 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102428368B (zh) * | 2009-05-05 | 2015-04-22 | B.R.A.H.M.S有限公司 | 患有内皮功能/功能障碍相关疾病的患者的基于血管活性激素的分层 |
CN103119446A (zh) * | 2010-06-18 | 2013-05-22 | B.R.A.H.M.S有限公司 | 预测癌症发生的生物标志物 |
Also Published As
Publication number | Publication date |
---|---|
CN101611314B (zh) | 2014-03-05 |
JP5379018B2 (ja) | 2013-12-25 |
US20100035289A1 (en) | 2010-02-11 |
US8436135B2 (en) | 2013-05-07 |
EP2111552A2 (de) | 2009-10-28 |
CN103884841A (zh) | 2014-06-25 |
US9726675B2 (en) | 2017-08-08 |
EP2111552B1 (de) | 2012-04-04 |
JP2010513879A (ja) | 2010-04-30 |
DE102006060112A1 (de) | 2008-06-26 |
CN103884841B (zh) | 2018-01-02 |
CN101611314A (zh) | 2009-12-23 |
ATE552504T1 (de) | 2012-04-15 |
US20130266961A1 (en) | 2013-10-10 |
ES2383711T3 (es) | 2012-06-25 |
WO2008074315A2 (de) | 2008-06-26 |
US8853355B2 (en) | 2014-10-07 |
US20150011017A1 (en) | 2015-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008074315A3 (de) | Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm | |
WO2008135038A3 (de) | Diagnose und risikostratifizierung mittels nt-proet-1 | |
WO2008040328A3 (de) | Diagnose von infektionen oder entzündungserkrankungen der atemwege und lunge assoziiert mit herzinsuffizienz | |
WO2008084402A3 (en) | Diagnosis and treatment of alzheimer's and other neurodementing diseases | |
WO2008055491A3 (de) | Diagnose und risikostratifizierung von diabetes mellitus mittels mr-proadm | |
WO2004103150A3 (en) | Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin | |
WO2007001342A3 (en) | Exhaled breath condensate collection and assay system and method | |
BRPI0811210A2 (pt) | Agente de formação de imagem, composição farmacêutica, métodos de preparação de um agente de formação de imagem, de formação de imagem óptica in vivo do corpo de um mamífero e de detecção, avaliação do estágio, diagnóstico, monitoração da progressão da doença ou monitoração do tratamento de câncer colorretal do corpo de um mamífero, e, kit para a preparação da composição farmacêutica. | |
WO2005098433A3 (en) | Diagnostic assays for alzheimer’s disease | |
WO2010041046A8 (en) | Granin proteins as markers of heart disease | |
WO2008058517A3 (de) | Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin ii | |
EP2293078A3 (de) | Verfahren zur Diagnose bakterieller Infektionen | |
WO2007044867A3 (en) | Imaging agents and methods of use thereof | |
CA2740134C (en) | Formulations targeting igfbp7 for diagnosis and therapy of cancer | |
MX342791B (es) | Ensayo elisa para la detección de vegf. | |
ATE523788T1 (de) | ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN | |
WO2009029971A8 (en) | Method for diagnosing the metabolic syndrome (ms) | |
WO2012044696A3 (en) | Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature | |
JP2012530253A5 (de) | ||
TW200734638A (en) | Method for the diagnosis of thromboembolic and coronary heart diseases | |
WO2005046720A3 (en) | Diagnosis, prognosis and treatment of pulmonary diseases using foxa2 | |
WO2010012828A3 (en) | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases | |
WO2011073905A8 (en) | Novel tumor markers | |
WO2009014342A3 (en) | Markers and kit for diagnosis of alzheimer's disease | |
WO2006113723A3 (en) | Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780047509.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07856143 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2009541760 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1166/MUMNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007856143 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12520159 Country of ref document: US |